Avalon Ventures is kick-starting the first biotech enterprise in its half-billion dollar portfolio deal with GlaxoSmithKline, launching a startup named Sitari Pharmaceuticals which will pursue research work out of Stanford University with an eye to developing a new drug for celiac disease.
Combination cancer therapies are all the rage these days in the oncology field. Now two of the giant players in the cancer R&D arena have decided to match their top prospects to see if they can make a bigger impact on melanoma.
Slightly less than a year after GlaxoSmithKline and Amicus Therapeutics reported that the first step in their Phase III program for the Fabry disease drug Amigal--or migalastat HCI--had ended in failure, the pharma giant has bowed out of its development collaboration.
If you take a big bet on an up-and-coming pharmaceutical maker and you turn out to be right, you should be able to reap some profit from your investment. That's what GlaxoSmithKline ($GSK) intends to do with a third of its stake in Aspen Pharmacare, a fast-growing South African drugmaker that has had a partnership with GSK since 2009.
Indian officials must have been glad to hear from GlaxoSmithKline CEO Andrew Witty. During a trip to the country, Witty told Indian media that the country's policies on pricing and patents are understandable, even reasonable, though they may pain the pharma industry.
Nobody making or selling drugs in India was happy when the government this year expanded price caps to nearly 350 drugs, but there seemed little for anyone to do.
GlaxoSmithKline expects increasing amounts of business from emerging markets, and so, to get ahead of the curve in India, the company is planning to build a new £85 million ($136.5 million) plant there, CEO Andrew Witty announced while in the country for a conference.
The pharma giant reported that the drug did not produce a statistically significant improvement in the risk of heart attack, stroke or death, though it added that "greater reductions" for some of the secondary endpoints warranted careful follow-up review as investigators considered its potential.
GlaxoSmithKline has racked up a slate of drug approvals this year, an impressive accomplishment for a company that had to endure a lengthy fallow period in R&D after it reorganized its extensive research operations.
Does the Justice Department's off-label marketing enforcement actually deter bad behavior? That's been up for debate as one drugmaker after another agreed to pay hundreds of millions of...